Healthcare Providers Share Results of Computer-Guided Insulin Dosing through Glytec During Diabetes Technology Society’s Virtual Hospital Meeting AdventHealth and CHI Franciscan Lead Three-Part Session with Data on Quality and Cost Improvements Achieved Through Electronic Glucose Management WALTHAM, Mass. (April 22, 2020) – Glytec, the only provider of insulin management software across the continuum of care, announced today that AdventHealth and …
Glytec, the pioneer of digital therapeutics, has hired an expert team of clinicians to help clients drive and sustain full adoption of best practices in glycemic management.
Hospitals and health systems looking to establish brand dominance, competitive distinction and clinical excellence in diabetes care can turn to a team of experts at Glytec dedicated to helping facilitate full adoption of best practices.
A presentation at ATTD 2019 by renowned diabetologist and researcher, Dr. Bruce Bode, showcased superior clinical and financial outcomes with Glytec’s eGlycemic Management System® versus usual care across multiple studies.
In conclusion to his plenary session at the 12th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2019), Dr. Bruce Bode delivered a call-to-action to an audience of his peers, espousing they do what is necessary to normalize glucose for all hospitalized patients (emphasis on ALL). He stressed that rates of hypoglycemia remain unacceptably high and use of sliding scale insulin continues to be prevalent despite abundant evidence denouncing it as unsafe and lacking efficacy. “Patients deserve better,” said Bode. With a clear focus on the solution to a decades-long problem of poor glucose control in hospitals, Bode described in detail the advantages of computerized decision support, highlighting data from multiple studies of Glytec’s FDA-cleared eGlycemic Management System® (eGMS®) that demonstrate consistently superior outcomes versus usual care, including significant reductions in hypoglycemia, 30-day readmissions and lengths of stay.
A diabetes webinar hosted by the American Hospital Association and sponsored by Glytec showcased why hypoglycemia prevention is imperative to the safety of patients and to the economics of healthcare delivery.
Featured speakers, Dr. Richard Pratley of Florida Hospital System and Dr. Steven Edelman of UC San Diego Health, recently delivered a unified message to several hundred senior healthcare professionals attending an American Hospital Association webinar: Hypoglycemia [low blood sugar] in the hospital is a major patient safety risk with significant clinical and financial implications. A case study presented by Pratley further revealed that insulin-managed patients who experience severe hypoglycemia, or blood sugar less than 40 mg/dL, have longer stays, higher readmission and mortality rates, and an overall cost of care $10,405 greater than patients whose blood sugar remains in the normal range.
Safety and efficacy of Glytec’s eGlycemic Management System® for diabetes therapy management, and its advantages over conventional methods, is further validated by four peer-reviewed studies.
Four new studies published in the January 2018 issue of Journal of Diabetes Science and Technology (JDST) demonstrate superior patient outcomes and organizational performance with Glytec’s eGlycemic Management System® (eGMS®) versus conventional, paper-based protocols. In all instances, which included both inpatient and outpatient settings, use of eGMS® for diabetes and insulin therapy management was observed to be safer and more effective than ‘usual care,’ with lower rates of hypoglycemia, faster resolution of diabetic ketoacidosis (DKA), expedited time to target glucose, and sustained reductions in A1c. Additionally, use of eGMS® led to substantive efficiency gains in provider workflows, fewer point-of-care tests, shorter lengths of stay, and full adoption of best practices, including 96% utilization of basal bolus insulin.
The move to quality ratings will put more pressure on hospitals to find ways to improve the standard of care while cutting costs.
A decade ago, the American Diabetes Association (ADA) called for hospitals to shift from sliding scale to subcutaneous basal-bolus insulin therapy for non-critically ill patients, but change has been slow in coming. Fear of hypoglycemia and concerns that staff would not be able to keep up with dosing demands of basal-bolus kept hospitals from upgrading to the standard of care.
One study presented at the International Hospital Diabetes Meeting observed first-year cost savings of nearly $7.5 million stemming from adoption of best practice for insulin therapy.
A series of studies and presentations included in the 6th International Hospital Diabetes Meeting highlighted the high cost of poor glucose management, and in particular, severe hypoglycemia (< 40 mg/dL) in the acute care setting. With thirty to forty percent of ALL hospitalized patients requiring insulin therapy, not just those with diabetes, the common problem of insulin mismanagement has significant impact on care quality, patient safety and patient experience, as well as cost and value.
Drs. Umpierrez and Cardona publish economic and clinical results of the GLUCO-CABG trial, leveraging Glytec’s Glucommander™ for personalized insulin dosing.
A study from Emory University published in the April 2017 issue of Journal of Diabetes and Its Complications (Cardona, et al. 2017) observes a near-20% reduction in perioperative complications, a 1.2-day reduction in ICU stay and a $3,654 reduction in per-patient hospitalization costs for coronary artery bypass graft (CABG) surgery. The reported outcomes, which included no severe hypoglycemia less than 40 mg/dL, were derived from an intensive glycemic control protocol supported by Glytec’s Glucommander™ for personalized insulin dosing.
The findings come as CMS targets cardiac procedures in both its hospital readmission reduction program and in a bundled payment model set to take effect July 1, 2017.
Glytec, which has FDA clearance for a cloud-based system to manage insulin dosing, selected MSHA as a research site for its electronic glucose management system, or eGMS. According to the studies Parsons and Mumpower presented in November at the Diabetes Technology Meeting showcase, eGMS produced sharp drops in readmission rates in 3 areas of cardiac care.
Two studies presented at the 16th Annual Diabetes Technology Meeting showcase readmission reductions as high as 68% with Glytec’s solution.
Two new studies presented at last week’s Diabetes Technology Meeting further validate the ability of Glytec’s eGlycemic Management System® (eGMS®) to achieve dramatic readmission reductions for patient populations at the center of new at-risk and value-based reimbursement models, including the CMS Hospital Readmission Reduction Program (HRRP) and impending bundled payment for coronary artery bypass graft surgery (CABG).
Our client, Hawaii Pacific Health, was named a HIMSS Enterprise Davies Award recipient based in part on its success implementing Glytec’s eGlycemic Management System® to support computer-based insulin dosing and a new hypoglycemia protocol.
The results were better glucose control with computer-directed insulin dosing system versus usual care. 39.8% of all glucose values in the ICU setting were above the recommended limit (glucose 180 mg/dl) with usual care. With computer-directed insulin dosing system for intravenous insulin, the hyperglycemia rate was much lower representing just 16.6% of all glucose values.
Using an algorithm to recommend insulin dosing, both in and out of the hospital, was shown to improve glycemic control and aid population health management.
The march toward value-based care is occurring on many fronts, with diabetes quality metrics front and center. Providers from giant hospital systems to primary care practices are looking for ways to find savings—and make patients healthier. In this mix is Glytec, a 10-year-old company founded on the idea that taking guesswork and time out of insulin dosing, first in hospital settings and then outside them, could dramatically reduce episodes of hypo- and hyperglycemia. This would provide savings and lead to better glycated hemoglobin (A1C) levels for patients with previously uncontrolled diabetes.
Wide range of studies further demonstrates significant impact in the emergency department, hospital and outpatient settings.
Glytec, the pioneer and leader in providing innovative, FDA-cleared glucose management software solutions, today announced that the company has presented five abstracts addressing a range of issues related to diabetes care at the American Diabetes Association’s 76th Scientific Sessions in New Orleans, Louisiana, June 10-14, 2016. The American Diabetes Association (ADA) brings together global leaders to discuss advancements in diabetes research and care.
The inclusion of a computer-guided program (Glucommander) as a component of diabetic ketoacidosis management was associated with significantly less hypoglycemia and faster time to normalization of blood glucose and bicarbonate than standard treatment of diabetic ketoacidosis, according to a new retrospective multicenter study.
The data were presented at the American Association of Clinical Endocrinologists (AACE) 25th Annual Scientific & Clinical Congress. The study also demonstrated a significant difference in length of hospital stay for patients treated with Glucommander compared with standard protocol (3.2 vs 4.5 days).
Our client, Orange Regional Medical Center, received a HIMSS Analytics Stage 7 Award based largely on its success implementing Glytec’s eGlycemic Management System® to support computer-based precision insulin dosing.
HIMSS Analytics® awarded Orange Regional Medical Center (ORMC), in Middletown, N.Y., with a Stage 7 Award. The award represents ORMC’s attainment of the highest level on the Electronic Medical Record Adoption Model (EMRAM)℠.
Electronic monitoring of blood sugar levels may diminish hypoglycemia and reduce length of stay in hospitalized diabetic ketoacidosis (DKA) patients, researchers reported here.
In one study, patients monitored with the Glucommander system reduced episodes of hypoglycemia by 56%, Joseph Aloi, MD, director of the Strelitz Diabetes Center at Eastern Virginia Medical School in Norfolk, and colleagues reported at the American Association of Clinical Endocrinologists meeting here. In a second study, they showed that the same system reduced the overall hospital length of stay by nearly 2 1/2 days in patients with diabetic ketoacidosis.
Leading hospital system achieves dramatic reductions in occurrences of hyperglycemia and hypoglycemia, reduces length of stay.
Sentara Healthcare, a 12-hospital, not-for-profit health system serving Virginia and northeastern North Carolina, widely recognized for clinical excellence and IT innovation, today announced that they have achieved dramatic improvements in inpatient glucose management through the utilization of the eGlycemic Management System® (eGMS®), developed by Glytec.